Overview
The current prospective observational pilot study aims to evaluate the endocrine profile of a single-injection protocol (single CFA + daily oral administration of CC).
Eligibility
Inclusion Criteria:
Age <= 40
AMH (Anti-Mullerian Hormone) 1.2-3.5 ng/ml or AFC 7-20
No family history of hereditary or chromosomal diseases
Body mass index (BMI) 18 to 30 kg/m2